Company: DVAX
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001029142-25-000117
Chunk: 251

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 251
---
Shingles$5,697 $3,882 $1,815 47%$12,684 $7,148 $5,536 77 %Plague (1)1,445 1,755 (310)(18)%2,685 3,077 (392)(13)%HEPLISAV-B and CpG 1018 adjuvant development1,274 1,707 (433)(25%)3,222 2,998 224 7 %Tdap14 1,094 (1,080)(99)%127 2,686 (2,559)(95)%Other4,819 2,969 1,850 62%10,331 5,670 4,661 82%Other research and development expenses:Facility costs536 662 (126)(19%)1,129 1,353 (224)(17%)Non-cash stock-based compensation2,834 2,881 (47)(2%)5,818 5,546 272 5%Total research and development$16,619 $14,950 $1,669 11%$35,996 $28,478 $7,518 26%

(1)In September 2021, we entered into an agreement with the DoD for the development of a recombinant plague vaccine utilizing CpG 1018 adjuvant. Under the agreement, we conducted a Phase 2 clinical trial and studies combining our CpG 1018 adjuvant with the DoD's rF1V vaccine. We are being fully reimbursed by the DoD for the costs of this study, which is recorded in other revenue in our condensed consolidated statements of operations. 

Research and development expenses increased by $1.7 million and $7.5 million for the three and six months ended June 30, 2025, respectively, compared to the same periods in 2024. The increase in research and development expenses was primarily driven by higher costs associated with our Shingles program due to the ongoing Phase 1/2 clinical trial, increased investment in the initiation and completion of enrollment for Part 1 of a Phase 1/2 clinical study for our pandemic influenza program, and continued work on IND-enabling activities for our Lyme disease program, which 

32

began in the first quarter of 2025. These increases were partially offset by reduced expenses following